New Delhi: Serum Institute of India CEO Adar Poonawalla has said that by the end of June this year, the company may launch another vaccine Covovax. The company has applied to the Drug Controller General of India (DGCI) for permission to start the vaccine trial. Serum Institute of India, which is making the vaccine in collaboration with the American company, Navavax, will launch it in the Indian market under the name of the local brand Covovax. Poonawalla said that the vaccine will be trialed under the partnership of Serum Institute of India with Novavax. However, in the trial results published so far, the vaccine has given excellent effective results against the coronavirus.
Poonawala said in a tweet, “We have a partnership with Novavax for the Coronavirus vaccine. The Novavax vaccine has produced excellent results in the recently published results. We have applied for a trial in India. Hopefully by June 2021 Will launch Kovovax. ” Pune-based Serum Institute of India is the world’s largest vaccine manufacturer. The Drug Controller General of India is investigating the application of the Serum Institute of India. This trial of the company will be a bridging trial, this trial is a way of supplementary trials, which are done for clinical data about the effects, safety, and dosage in new areas.
Earlier, Executive Director of Serum Institute, Umesh Shaliagaram, in a conversation with News18, said that the company is ready to start a bridging trial in the country and once the permission is granted, the company can start it in February. He said that the data of the vaccine against the new forms of corona virus is arousing hope. The good thing is that the corona virus found in South Africa has come to light when the trial of vaccine is going on in the African country.
In September 2020, Novavax announced a partnership with Serum Institute of India for 2 billion vaccines of the coronavirus, the vaccine would be sold in India under the name of Covovax and developed by Novavax.
